Comprehensive pan-cancer analysis and experiments revealed R3HDM1 as a novel predictive biomarker for prognosis and immune therapy response
Overall, this study proposes that R3HDM1 expression is a promising biomarker for predicting the prognosis of cancer, especially lung adenocarcinoma, and the efficacy of immunotherapy, demonstrating the rationale for further exploration in the development of anti-tumor therapies.
Authors
- Zhitong Bing (ORCID: https://orcid.org/0000-0002-6302-8612)
- Jiawei Liu (ORCID: https://orcid.org/0000-0002-5794-1683)
- Junling Wang (ORCID: https://orcid.org/0000-0002-5839-4685)
Institutions
- Chinese Academy of Sciences (CN)
- Gansu Provincial Hospital (CN)
- Institute of Modern Physics (CN)
- Gansu Provincial Science and Technology Department (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Frontiers in Genetics
- Published
- 2024-09-23
- DOI
- https://doi.org/10.3389/fgene.2024.1404348
- Citations
- 3
- Primary Topic
- Cancer-related molecular mechanisms research
- Type
- article
- Field-Weighted Citation Impact
- 0.86